GlassScriptPhysician profile
Alan W Purvis
NPI 1932193414
$9,301.16
in general payments reported to CMS, 2019-2025
37 companies · $1,286 in 2025
The $1,286 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,539 · 2020: $1,142 · 2021: $1,646 · 2022: $1,375 · 2023: $978 · 2024: $1,336 · 2025: $1,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,600.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,833.11 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,158.20 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $936.22 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $477.85 | 2019-2025 | Dupixent |
| Philips North America LLC | $409.68 | 2019-2022 | |
| Amgen INC. | $322.54 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $322.21 | 2019-2025 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $314.55 | 2019-2022 | |
| Mylan Specialty L.P. | $297.16 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $241.28 | 2023-2025 | Glassia, Cuvitru, Hyqvia |
| Electromed, INC. | $216.23 | 2021-2025 | Smartvest |
| Intuitive Surgical, INC. | $211.85 | 2024 | |
| United Therapeutics Corporation | $194.02 | 2021-2025 | Tyvaso |
| Genzyme Corporation | $152.21 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $119.96 | 2021-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $119.14 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $112.81 | 2019-2023 | Opsumit |
| Merck Sharp & Dohme LLC | $91.68 | 2019-2024 | Keytruda |
| Genentech USA, INC. | $88.11 | 2019-2022 | |
| Circassia INC. | $64.95 | 2019-2020 | |
| Fisher & Paykel Healthcare INC | $64.87 | 2021-2022 | |
| Viatris Specialty LLC | $57.32 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $56.64 | 2023-2025 | Sunosi |
| Shire North American Group INC | $47.33 | 2019 | |
| Vifor Pharma, INC. | $46.82 | 2025 | Zemaira |
| Melinta Therapeutics, LLC | $46.32 | 2020 | |
| Sunovion Pharmaceuticals INC. | $46.27 | 2019-2020 | |
| Verona Pharma, INC. | $42.39 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $37.89 | 2025 | |
| Advanced Respiratory, INC | $35.18 | 2021 | |
| Tactile Systems Technology INC | $34.10 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Novartis Pharmaceuticals Corporation | $29.84 | 2019-2020 | |
| Allergan, INC. | $22.98 | 2020 | |
| Covidien LP | $16.97 | 2019 | |
| Abbvie INC. | $16.63 | 2021 | |
| 3b Medical, INC. | $11.26 | 2023 | Luna |
| Inogen, INC. | $4.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Purvis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.